Experience with the use of immunobiological drugs in the treatment of patients with severe bronchial asthma and comorbidities
| Autor: | V. P. Sereda, D. A. Svirido, M. V. Komarov, O. A. Smulskaya |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Meditsinskiy sovet = Medical Council. :18-27 |
| ISSN: | 2658-5790 2079-701X |
| Popis: | Introduction. The accumulation of clinical experience in the use of biological therapy in patients with severe bronchial asthma (SBA) in real-world clinical practice with the possible identification of additional, previously undescribed clinical results is of practical interest.Aim. The goal of the study is to present results of observational study that reflects experience of using benralizumab in SBA in real-world clinical practice in city of Saint Petersburg.Materials and methods. We presents results of more than 1 year observation of 18 patients with eosinophilic SBA (12 females, 6 males, age from 28 to 74, average age 55 ± 11.9 years). Patients received benralizumab in addition to standard medical management. Conducted clinical, laboratory, functional examination of patients, assessment of the frequency of exacerbations and additional clinical effects.Results. It was shown that the inclusion of benralizumab in complex therapy led to a significant improvement in disease control, improved bronchial conduction, a significant decrease in blood eosinophilia and a reduction in the number of exacerbations. Clinical examples are given that evidence to the stabilizing effect of this therapy on the course of recurrent nasal polyposis and the positive effects on the course of eosinophilic granulomatous polyangiitis, manifested by SBA.Conclusions. In real clinical practice, the possibility of a significant improvement in control in patients with SBA with the use of biological therapy has been confirmed. At the same time, data have been obtained that will allow expanding the indications for the use of benralizumab in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|